LAST DRAW OF THE BOND FINANCING OF €10M MADE ON MARCH 10, 2022
SUCCESS OF LA 1
time
STAGE OF THE GROUP’S TRANSFORMATION PLAN AIMED AT IMPROVING ITS FINANCIAL SITUATION
Houdeng-Goegnies (Belgium), March 11, 2022, 6 p.m. – Pharmasimple (ISIN Code: BE0974302342. Ticker: ALPHS), a company specializing in the online sale of parapharmaceutical products among the leaders in its sector in Europe, announces that it carried out yesterday the last drawing of €0.5 million on its €10 million line of bonds convertible into shares resulting from an investment agreement entered into with Alpha Blue Ocean in August 2021.
As indicated in a press release dated March 3, this line of financing made it possible to settle supplier accounts and repay part of the short-term bank debts. This normalization, made necessary after an exceptional year 2020 in terms of WCR due to strong demand for Covid-19 prevention products, now allows Pharmasimple to continue its activity under favorable conditions with a satisfactory level of stocks, outstanding suppliers and cash.
The improvement in the group’s financial situation, made possible by the implementation of quasi-equity financing, is a first step in the transformation of Pharmasimple. This will now be able to continue with the implementation of the strategy of bringing together pharmacies in order to generate maximum synergies between the offline sales of pharmacies and the online distribution of Pharmasimple’s historic platforms.
Michael Willems, CEO of Pharmasimple says:
“We thank Alpha Blue Ocean for supporting us in this first stage of the group’s transformation and are now in working order to bounce back and begin a new cycle of sustainable growth for Pharmasimple”.
Next publication: 2021 annual results: April 13, 2022 after market close.
contacts:
|
Society |
Communication |
About Pharmasimple:
Pharmasimple, specializing in the online sale of parapharmaceutical products, is one of the main players in France. The company offers more than 120,000 references of cosmetic and dermo-cosmetic products, medical accessories and food supplements. In 2021, Pharmasimple achieved sales of €30.0 million. The Group aims to become one of the leaders in its sector in Europe. Pharmasimple benefits from the “Innovative Company” label awarded by Bpifrance. Pharmasimple shares are listed on the Euronext Growth market. ISIN code: BE0974302342. Mnemonic: ALPHS.
This post has the “? Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
lpyck8ZtY2mUmGtsY5yam5dsZphpx2aYmGXKmpadaJvImXJgyJtqbpzLZnBkmmls
– To check this key:
https://www.security-master-key.com.
Regulated information:
Inside information:
– Other press releases
Full and original press release in PDF format:
https://www.actusnews.com/news/73546-cp-pharmasimple-oca-last-draw-11.03.2022.pdf
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com